A previous study in a completed clinical trial on mild Alzheimer disease suggested that baseline plasma NfL, which is a neurological biomarker, holds independent information on short-term cognitive decline [40]. The gene discussed is NEFL; the disease is early-onset autosomal dominant Alzheimer disease.